Houston Car Accident Lawyers
Instances of Invokana kidney failure have led to a number of different patients filing lawsuits against the manufacturer of the drug.
A new class of diabetes drugs that was promoted as safe and effective have been named in a number of different lawsuits based on severe side effects. One such example of these side effects include Invokana kidney failure.
Researchers have recently completed studies showing that this new class of diabetes drugs including Jardiance and Invokana are connected to a higher rate of kidney failure than similar diabetes treatments.
The renal failure rates were much higher for Invokana than other drugs in the same class, according to a recent study.
The research outcomes were published in Nutrition, Metabolism and Cardiovascular Diseases after Israeli researchers identified that there was a strong connection between acute renal failure and SGLT-2 inhibitors. This kidney failure rate was identified using data from the FDA adverse event reporting system. Initially, Invokana was approved by the FDA in March 2013.
Since then, other SGLT-2 inhibitors have been approved, including Jardiance, Xigduo, and Invokamet. Invokana remains the most popularly used despite the risks of kidney failure and other serious side effects.
Many patients who have experienced unexplained and sudden side effects may need support provided by a settlement or lawsuit. The pain associated with renal failure could lead to costly medical bills, lost time at work, and more. As with other allegedly defective drugs, this situation could lead a plaintiff to file a lawsuit to help recover compensation to pay for these losses.
Some of the most serious side effects tied to Invokana have to do with kidney damage; if a kidney issue is not caught quickly by a medical professional, the injured plaintiff could suffer grave consequences.
Adverse Event Reports Detail Problems with Invokana Kidney Failure
Between early 2013 and September 2016, adverse event reports were filed with the FDA, indicating that a higher proportion of reports were connected to acute renal failure for those people using Invokana.
Nearly, 19,000 of the 3.8 million reports filed with the FDA during that time period were connected to SGLT-2 inhibitors. More than 1,200 cases of acute renal failure were linked to medications such as Jardiance and Invokana.
Many patients who have suffered kidney failure may not realize the risks until they have been taken to the hospital and diagnosed with this serious condition.
If doctors are not able to respond quickly, this can be a very serious and life-threatening situation.
The research findings for kidney failure associated with Invokana indicated that the proportion of reports including acute renal failure allegations were nearly three times higher when the cases involved an SGLT-2 inhibitor.
The highest proportion of kidney failure events were associated with Invokana at 7.3 percent compared with Jardiance at 4.7 percent.
Although these medications were promoted as superior to other diabetes treatment options, patients who suffer Invokana kidney failure may be eligible to pursue a lawsuit with the help of lawyers at McDonald Worley.